RE:RE:RE:FYIWe cannot know about partnership deals until the company decides to reveal info about it. I think it is safe to conclude nothing is going on a NASH partnership but also safe to believe preliminary discussions could be happening on the cancer front. Enrollment in the restarted trial should start around quarter end. No announcement has been made about when to expect top line results on the restarted trial. But the drug should work quickly if it is going to produce tumor shrinkage. I think if there are going to be good results THTX will know within three months of a patient being enrolled, if not earlier. So, it depends on when enrollees start and if THTX decides to report results. If the results are good, we should hear sooner rather than later. If we don't hear anything by mid-October that might not be a good sign. There is no obvious and/or significant news flow that I am aware of between 2Q and 3Q financial results. They could speak at conferences between those two dates and give cancer updates if they do. But remember the CEO said at such a conference last September that TH-1902 might be the key to unlocking the cancer cell. So, things can change quickly as the pause showed us. The NASDAQ listing issue is not a near term issue as 6 month extensions are normally given, pushing that issue out to February 2023. So, even though the company has not said much about these issues, we can still figure a lot out by thinking it through. Hopefully, THTX will clarify some of these things during the second quarter conference also we don't have to think so hard!
Trogarzon wrote: Do we know if they are working on a partnership at the moment in Nash or Onco. Do we have an idea of the enrolment of the resarted Th1902 study. When do we expect top line results. What will be the news flow before Th1902 results and when can we exect those. What's the strategy in regards to the Nasdaq ultimatum. I mean these are all basic questions we don't have much of a clue about. We have hope maybe... we're running on hope and prayer.